This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Molina Healthcare (MOH) Q3 Earnings Beat on Membership Growth
by Zacks Equity Research
Molina Healthcare's (MOH) third-quarter results gain from changes in the member mix and a growing premium base. Management reiterates its 2023 adjusted EPS guidance to be a minimum of $20.75.
Teladoc Health (TDOC) Q3 Loss Narrows on Integrated Care Strength
by Zacks Equity Research
Teladoc Health's (TDOC) Q3 results were aided by membership growth in the Integrated Care unit as well as strong BetterHelp revenues. Management presently expects 2023 net loss per share to be within $1.50-$1.40.
Quest Diagnostics (DGX) Tops Q3 Earnings, Gross Margin Dips
by Zacks Equity Research
Quest Diagnostics' (DGX) base business growth reflects the company's ongoing efforts to partner with health plans, hospitals and physicians amid a continued return to care.
Compared to Estimates, Quest Diagnostics (DGX) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Quest Diagnostics (DGX) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Quest Diagnostics (DGX) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Quest Diagnostics (DGX) delivered earnings and revenue surprises of 1.37% and 1.66%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Encompass Health (EHC) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Encompass Health (EHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Quest Diagnostics (DGX) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Quest Diagnostics (DGX) third-quarter 2023 results are likely to reflect continued strength in the base business.
Quest Diagnostics (DGX) Gains From New Alliances Amid FX Woes
by Zacks Equity Research
Quest Diagnostics' (DGX) recent acquisition of New York-Presbyterian's outreach assets adds to volume growth within Physician Lab Services.
Earnings Preview: Quest Diagnostics (DGX) Q3 Earnings Expected to Decline
by Zacks Equity Research
Quest Diagnostics (DGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Quest Diagnostics (DGX) to Boost Lab Services With New Pact
by Zacks Equity Research
Quest Diagnostics (DGX) latest deal will boost dialysis laboratory testing and reduce the laboratory costs of dialysis programs for ESRD patients.
Should Value Investors Buy Quest Diagnostics (DGX) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Reasons to Retain Quest Diagnostics (DGX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Quest Diagnostics (DGX), backed by collaborations with health plans and upbeat guidance.
Quest Diagnostics (DGX) to Aid Health Equity With New Pact
by Zacks Equity Research
Quest Diagnostics (DGX) and Americares will provide 10 clinics with no-cost diagnostic services for a year to help patients manage chronic disease.
Quest Diagnostics' (DGX) AAV Test Gets FDA's Breakthrough Nod
by Zacks Equity Research
Quest Diagnostics (DGX) achieves breakthrough designation for AAVrh74 ELISA and expands collaboration with Sarepta Therapeutics.
Why Is Quest Diagnostics (DGX) Down 0.9% Since Last Earnings Report?
by Zacks Equity Research
Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Quest Diagnostics (DGX) Base Volume Aids Amid Low COVID Tests
by Zacks Equity Research
Quest Diagnostics (DGX) continues to witness growth momentum in the cardiometabolic, endocrinology, infectious disease and carrier and prenatal genetic screening services.
Reasons to Retain Quest Diagnostics (DGX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Quest Diagnostics (DGX) on the strength of the base business performance and acquisitions.
Quest Diagnostics (DGX) Q2 Earnings Beat Estimates, FY View Up
by Zacks Equity Research
Quest Diagnostics (DGX) delivers better-than-expected earnings and revenues in the second quarter of 2023.
Quest Diagnostics (DGX) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Quest Diagnostics (DGX) delivered earnings and revenue surprises of 3.14% and 4.22%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
MedTech Stocks' Q2 Earnings Due on Jul 26: DGX, TMO and More
by Urmimala Biswas
MedTech companies' second-quarter results are likely to reflect a year-over-year decline. Let's see how DGX, TMO, EW and ALGN fare this time.
Quest Diagnostics (DGX) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Quest Diagnostics (DGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Quest Diagnostics (DGX) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Quest Diagnostics (DGX) second-quarter results are likely to have reflected the solid base business performance and benefits from acquisitions.
Reasons to Retain Quest Diagnostics (DGX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Quest Diagnostics (DGX) on stronger base volume recovery and growth from strategic acquisitions.
Quest Diagnostics (DGX) Brings New Test for Prostate Cancer
by Zacks Equity Research
Quest Diagnostics (DGX) collaborates with Envision Sciences to bring a novel prosate cancer biomarker test.
Quest Diagnostics' (DGX) New Pact to Get Home Fertility Test
by Zacks Equity Research
The Proov Confirm home collection kit can be purchased now on Quest Diagnostics' questhealth.com for $29.